Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rezivertinib - Beta Pharma

Drug Profile

Rezivertinib - Beta Pharma

Alternative Names: BPI-7711; Rezetinib mesylate

Latest Information Update: 04 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beta Pharma
  • Class Amides; Amines; Antineoplastics; Indoles; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer

Most Recent Events

  • 09 Sep 2022 Effiicacy and adverse events data from a phase I/II trial in Non-small cell lung cancer presented at 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 03 Jun 2022 Interim efficacy and adverse events data from a phase IIb trial in non-small cell lung cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 27 Apr 2022 Beta Pharma expects NDA approval for Non-small cell lung cancer in the second or third quarter of 2022 (Beta Pharma pipeline, April 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top